Mesa Laboratories (MLAB) Cash & Equivalents (2010 - 2025)

Mesa Laboratories has disclosed Cash & Equivalents across 16 years of filings, most recently posting $29.0 million for Q4 2025.

• Cash & Equivalents for Q4 2025 came in at $29.0 million, up 6.05% year-over-year; the trailing twelve-month figure through Dec 2025 was $29.0 million (up 6.05% YoY), and the FY2025 annual result was $27.3 million, down 3.17% from the prior year.
• Cash & Equivalents came in at $29.0 million for Q4 2025 at Mesa Laboratories, up from $20.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $278.3 million in Q3 2021 to a low of $20.4 million in Q3 2025.
• The 5-year median for Cash & Equivalents is $30.7 million (2023), against an average of $67.8 million.
• Across the five-year window, Cash & Equivalents soared 224.24% in 2021 and slumped 88.37% in 2022, its largest moves.
• Mesa Laboratories' Cash & Equivalents stood at $51.7 million in 2021, then sank by 49.52% to $26.1 million in 2022, then climbed by 8.13% to $28.2 million in 2023, then declined by 3.2% to $27.3 million in 2024, then climbed by 6.05% to $29.0 million in 2025.
• The last three Cash & Equivalents figures came in at $29.0 million (Q4 2025), $20.4 million (Q3 2025), and $21.3 million (Q2 2025), per Business Quant data.